Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

922333

registered interest
date	12/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Packaging
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of increased uniformity of medication packaging across manufacturers to enable the efficient identification of all medicines.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	152755
answer	answer is ministerial correction date of answer 20/06/2018 answer text <p>The Government has produced guidance in conjunction with experts in clinical practice and in the field of design for those who produce medicines packaging which recommends the judicious use of colour to ensure medicines are well differentiated to reduce the likelihood of error. In developing the principles within this guidance, the views of healthcare professionals and patients have been considered.</p><p> </p><p>While there are detailed legal requirements with respect to the content of the information provided on the packaging there are no provisions with respect to colour and design of the packaging when presented to the market place.</p><p> </p><p>Published research points to the similarity of packaging contributing adversely to selection errors in the pharmacy and other clinical settings. In addition, we are also mindful of the views expressed by patients whereby differences in appearance of medicines from different suppliers can be confusing. Where specific safety issues have been identified, for example with medicines containing warfarin, particular colours both for the tablets and the packaging have been adopted as an industry standard.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 152756 152757 question first answered 20/06/2018 16:03:25 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4079 label Biography information for Julian Sturdy

922337

registered interest
date	12/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Packaging
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations he has received on the desirability of increased uniformity of medication packaging across manufacturers from the (a) public and (b) health service.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	152756
answer	answer is ministerial correction date of answer 20/06/2018 answer text <p>The Government has produced guidance in conjunction with experts in clinical practice and in the field of design for those who produce medicines packaging which recommends the judicious use of colour to ensure medicines are well differentiated to reduce the likelihood of error. In developing the principles within this guidance, the views of healthcare professionals and patients have been considered.</p><p> </p><p>While there are detailed legal requirements with respect to the content of the information provided on the packaging there are no provisions with respect to colour and design of the packaging when presented to the market place.</p><p> </p><p>Published research points to the similarity of packaging contributing adversely to selection errors in the pharmacy and other clinical settings. In addition, we are also mindful of the views expressed by patients whereby differences in appearance of medicines from different suppliers can be confusing. Where specific safety issues have been identified, for example with medicines containing warfarin, particular colours both for the tablets and the packaging have been adopted as an industry standard.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 152755 152757 question first answered 20/06/2018 16:03:25 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4079 label Biography information for Julian Sturdy

922344

registered interest
date	12/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Packaging
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the implications for the safety of patients of the variety in packaging of the same medicines; and if he will make a statement.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	152757
answer	answer is ministerial correction date of answer 20/06/2018 answer text <p>The Government has produced guidance in conjunction with experts in clinical practice and in the field of design for those who produce medicines packaging which recommends the judicious use of colour to ensure medicines are well differentiated to reduce the likelihood of error. In developing the principles within this guidance, the views of healthcare professionals and patients have been considered.</p><p> </p><p>While there are detailed legal requirements with respect to the content of the information provided on the packaging there are no provisions with respect to colour and design of the packaging when presented to the market place.</p><p> </p><p>Published research points to the similarity of packaging contributing adversely to selection errors in the pharmacy and other clinical settings. In addition, we are also mindful of the views expressed by patients whereby differences in appearance of medicines from different suppliers can be confusing. Where specific safety issues have been identified, for example with medicines containing warfarin, particular colours both for the tablets and the packaging have been adopted as an industry standard.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 152755 152756 question first answered 20/06/2018 16:03:25 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4079 label Biography information for Julian Sturdy